Plug Power hydrogen stock slump and pharma picks spotlighted by analysts

Analysts note that Plug Power's shares, after soaring 83% in early 2026, have erased those gains, falling back below $3 as shareholder dilution and high hydrogen costs pressure the company. While the firm reports improving gross margins and sales growth, the rapid increase in shares outstanding—131% over three years—raises concerns about long‑term profitability.

At the same time, market watchers highlight a watchlist of pharmaceutical companies expected to benefit from trends such as GLP‑1 obesity drugs and broader healthcare rebounds. The list includes Eli Lilly, AbbVie, Abbott Laboratories, Bristol‑Myers Squibb and Gilead Sciences, each noted for strong product pipelines and recent trading volume.

Both stories illustrate continued investor focus on sectors seen as future growth drivers despite near‑term valuation and operational challenges.